Detalhe da pesquisa
1.
The risk of secondary progressive multiple sclerosis is geographically determined but modifiable.
Brain
; 146(11): 4633-4644, 2023 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37369086
2.
The effect of sleep disorders on quality of life in patients with epilepsy: A multicenter study from Turkey.
Epilepsy Behav
; 150: 109568, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38141572
3.
Risk of secondary progressive multiple sclerosis after early worsening of disability.
J Neurol Neurosurg Psychiatry
; 94(12): 984-991, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37414538
4.
Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network.
J Neurol Neurosurg Psychiatry
; 94(1): 23-30, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36171104
5.
Disability accrual in primary and secondary progressive multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 94(9): 707-717, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37068931
6.
Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial.
J Neurol Neurosurg Psychiatry
; 94(12): 1004-1011, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37414534
7.
External validation of a clinical prediction model in multiple sclerosis.
Mult Scler
; 29(2): 261-269, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36448727
8.
Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry.
Mult Scler
; 29(2): 221-235, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36433775
9.
Impact of COVID-19 vaccination or infection on disease activity in a radiologically isolated syndrome cohort: The VaxiRIS study.
Mult Scler
; 29(9): 1099-1106, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37322880
10.
Comparative effectiveness in multiple sclerosis: A methodological comparison.
Mult Scler
; 29(3): 326-332, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36800908
11.
Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis.
Eur J Neurol
; 30(4): 1014-1024, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36692895
12.
Is Mediterranean diet associated with multiple sclerosis related symptoms and fatigue severity?
Nutr Neurosci
; 26(3): 228-234, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35143375
13.
The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis.
Neurol Sci
; 44(6): 2121-2129, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36689010
14.
Retrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE).
Turk J Med Sci
; 53(1): 323-332, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36945929
15.
Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.
N Engl J Med
; 381(7): 614-625, 2019 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31050279
16.
Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national registry.
J Neurol Neurosurg Psychiatry
; 2022 Sep 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-36180218
17.
Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS.
Mult Scler
; 28(11): 1752-1761, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35373638
18.
Confirmed disability progression as a marker of permanent disability in multiple sclerosis.
Eur J Neurol
; 29(8): 2321-2334, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35582938
19.
Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis.
Mult Scler
; 27(5): 755-766, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32538713
20.
Determinants of therapeutic lag in multiple sclerosis.
Mult Scler
; 27(12): 1838-1851, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33423618